Funding for this research was provided by:
National Cancer Institute (K08CA190770, R01CA171558, R01CA128799)
Received: 27 January 2020
Accepted: 17 April 2020
First Online: 12 May 2020
Ethics approval and consent to participate
: Institutional Review Board approval was obtained at all participating sites, and patients consented to participate. All data were collected in adherence with the IRB protocols.
: All patients consented to participate in this study.
: SMF, NBF, SKB, LC, KF, AN, TK, RF, IMA, and DC report no potential conflicts of interest. EJG: advisory board for Novartis; DLR: advisory board for AstraZeneca and Mankind and consultant for Janssen; EP: stock ownership in Remedy Pharmaceuticals, Angiocrine, Viewpoint, TMRW; BK: advisory board for and honoraria from Genentech; NAB: research funding from Pfizer.